EC50: 0.63 μM (β-Catenin)
WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility.
WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β -catenin pathway and most likely through inhibition of Dkk-1.
Career Henan Chemica Co
联系商家时请提及chemicalbook，有助于交易顺利完成！